Overview
Aditya Halthore, MD, serves as Assistant Professor in the Department of Radiation Oncology and Molecular Radiation Sciences and Director of Safety and Quality at the Johns Hopkins University School of Medicine. Listen to Dr. Halthore's On Target podcast episode to learn more about his work. Dr. Halthore is an expert in proton therapy and specializes in genitourinary and thoracic cancers. His specific interests include prostate, bladder, lung, esophageal, and thymic cancers, and he is committed to developing personalized treatment strategies for every patient. Dr. Halthore was previously recognized as a Howard Hughes Medical Institute (HHMI)/National Institutes of Health (NIH) Scholar and his research interests include grant funded clinical trials focused on the novel utilization of radiation and imaging techniques, such as spatial fractionation (proton GRID) therapy for the treatment of bulky cancers. He is also involved in using dual-energy CT and functional MRI studies that aim to improve functional radiation planning and the assessment of radiation-induced changes. As an educator, Dr. Halthore serves as Course Director for the Johns Hopkins Proton Therapy Certificate Program. He actively participates in student, resident, and fellow lectureship and mentorship across the Johns Hopkins health system. Dr. Halthore participates in several national-level initiatives including as a member of the American Society of Therapeutic Radiation Oncology (ASTRO) Guidelines Subcommittee and as a board member and ASTRO liaison to the Medical Dosimetry Certification Board (MDCB).
Dr. Halthore is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Prostate Cancer, Small Cell Lung Cancer (SCLC), Marginal Zone Lymphoma (MZL), and Familial Prostate Cancer.
His clinical research consists of co-authoring 22 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5255 Loughboro Road Northwest, Washington, DC 20016
300 Mason Lord Drive, Kimmel Cancer Center, Baltimore, MD 21224
5255 Loughboro Road Northwest, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Narang is an Assistant Professor in the Johns Hopkins Department of Radiation Oncology & Molecular Sciences. A former chief resident in the department, Dr. Narang now specializes in radiation treatment for gastrointestinal malignancies, including pancreatic cancer, colorectal cancer, hepatobiliary malignancies, and gastric cancer. Dr. Narang has an interest in expanding multi-disciplinary care for patients with gastrointestinal malignancies. Make A Gift. Dr. Narang is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, Pancreaticoduodenectomy, and Pancreatectomy.
Sibley Memorial Hospital
"Dr. Rachit Kumar is a radiation oncologist specializing in genitourinary and gastrointestinal cancers. He is dedicated to patient-centered care, finding the most effective outcome for each patient and using the latest advances to minimize treatment time and side-effects. Dr. Kumar is frequently published in peer-reviewed journals on new methods of radiation therapy and the benefits to patient outcomes. He is a member of the Johns Hopkins Kimmel Cancer Center and treats patients at both Sibley Memorial Hospital and Suburban Hospital. Selected Publications Kumar R, Tchelebi LT, Anker CJ, Sharma N, Bianchi NA, Dragovic J, Goodman KA, Herman JM, Jiang Y, Jones WE, Kenney TJ, Lee P, Kundranda MK, Russo S, Small W, Suh WW, Yee N, and Jabbour SK. “American Radium Society (ARS) Appropriateness Use Criteria (AUC) for Loco-Regional Gastric Adenocarcinoma: Systemic Review and Guidelines.” American Journal of Clinical Oncology. 2022 Sep 1;45(9):391-402. Rooney MK, Traube B, Khan MK, Kumar R, and Walker GV. “Factors associated with image guided radiation therapy image rejection in a multi-site institution.” JCO Oncology Practice. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, and Kuban DA. “Contemporary Prostate Cancer Treatment Choices in Multidisciplinary Clinics Referenced to National Trends.” Cancer. Tang C, Lei X, Smith GL, Pan HY, Hoffman K, Kumar R, Chapin BF, Shih YC, Frank SJ, and Smith BD. ""Influence of Geography on Prostate Cancer Treatment Coice: An Analysis of the National Medicare Database."" International Journal of Radiation Oncology Biology Physics. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Aparicio A, Zurita-Saavedra A, Chun S, Reddy J, Choi S, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Tu SM, Pilie P, Kovitz C, Kumar R, Roberts T, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn and PG. “Addition of local consolidative therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter randomized phase II basket trial.” JAMA Oncology.". Dr. Kumar is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, and Prostate Cancer.
Medstar Medical Group Ii LLC
Keith Unger is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Unger is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Anal Cancer, and Adult Soft Tissue Sarcoma. Dr. Unger is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Prostate CancerDr. Halthore isDistinguished. Learn about Prostate Cancer.
- Advanced
- ALK-Positive Non-Small Cell Lung Cancer
- Breast CancerDr. Halthore isAdvanced. Learn about Breast Cancer.
- Familial Prostate CancerDr. Halthore isAdvanced. Learn about Familial Prostate Cancer.
- Lung AdenocarcinomaDr. Halthore isAdvanced. Learn about Lung Adenocarcinoma.
- Marginal Zone Lymphoma (MZL)Dr. Halthore isAdvanced. Learn about Marginal Zone Lymphoma (MZL).
- Pleuropulmonary BlastomaDr. Halthore isAdvanced. Learn about Pleuropulmonary Blastoma.
- Experienced
- Adult Soft Tissue SarcomaDr. Halthore isExperienced. Learn about Adult Soft Tissue Sarcoma.
- EGFR Positive Lung CancerDr. Halthore isExperienced. Learn about EGFR Positive Lung Cancer.
- Fibrodysplasia Ossificans ProgressivaDr. Halthore isExperienced. Learn about Fibrodysplasia Ossificans Progressiva.
- Large-Cell Lung CarcinomaDr. Halthore isExperienced. Learn about Large-Cell Lung Carcinoma.
- Laryngeal CancerDr. Halthore isExperienced. Learn about Laryngeal Cancer.
- Lung CancerDr. Halthore isExperienced. Learn about Lung Cancer.